Literature DB >> 8325600

Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis.

E Stechemesser1, R Klein, P A Berg.   

Abstract

The isolation of a marker antigen from rat liver and pancreas tissue, which reacts with antibodies in a subtype of autoimmune hepatitis by complement fixation test, enzyme-linked immunosorbent assay and Western blot, is described. The liver-pancreas antigen could be detected in tissue from different human or animal organs, but liver and pancreas yielded the highest activity. A highly specific antigen fraction was obtained by gel filtration and ion exchange chromatography with a 100,000 g supernatant from rat liver tissue, and this preparation was shown to be devoid of nuclear, mitochondrial and microsomal antigens and cytokeratin 8 and 18, as demonstrated by appropriate marker antibodies. These data and absorption studies with cell organelles indicate that liver-pancreas antigen is a cytosolic protein. By Western blotting, two major epitopes at molecular weights 52 kD and 48 kD could be visualized. Sera from 175 patients previously shown to have high complement-fixing activity to a nonpurified liver-pancreas antigen fraction were further analyzed. All were positive by enzyme-linked immunosorbent assay with the purified liver-pancreas antigen fractions, and 111 were also positive by Western blot. Eighty-six sera reacted with the 52-kD determinant, 33 with the 48-kD determinant and 2 with both determinants. In 117 of the 175 patients, antibody to liver-pancreas antigen was associated with other autoantibodies known to characterize subgroups of autoimmune hepatitis. Thus 19 patients had antibodies to nuclei and 96 to actin but none to liver-kidney microsomes, hereby suggesting that antibody to liver-pancreas antigen may define another subgroup of autoimmune hepatitis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325600

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis.

Authors:  M Costa; J L Rodríguez-Sánchez; A J Czaja; C Gelpí
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 4.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

Review 5.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

6.  The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

Authors:  I G McFarlane
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

7.  Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.

Authors:  Reinhild Klein; Eva Hintz; Gerd Staehler
Journal:  BMJ Case Rep       Date:  2012-07-13

Review 8.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 9.  Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus.

Authors:  N V Naoumov; A L Eddleston
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

Review 10.  Autoimmune liver serology: current diagnostic and clinical challenges.

Authors:  Dimitrios-P Bogdanos; Pietro Invernizzi; Ian-R Mackay; Diego Vergani
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.